Best Telehealth GLP-1 Providers of 2026

Compounded vs Brand-Name: The Distinction Most Pages Skip

When you sign up for a 'GLP-1 program' through telehealth, you are usually being prescribed one of two materially different products. The first is FDA-approved Wegovy or Zepbound — manufactured by Novo Nordisk and Eli Lilly respectively, with the same active ingredient and the same labeled dosing as the medication used in pivotal randomized trials. The second is compounded semaglutide or compounded tirzepatide, prepared by a state-licensed compounding pharmacy, not reviewed by the FDA for safety, efficacy, manufacturing quality, or labeling.

Compounded does not mean illegal. Under section 503A of the FD&C Act, traditional compounding pharmacies can prepare a copy of an FDA-approved drug only when that drug appears on the FDA's drug-shortage list. Throughout most of 2023 and 2024, both semaglutide and tirzepatide were on the list — making compounded versions broadly available through telehealth. Once the FDA removes a drug from the shortage list, the legal pathway for compounded copies narrows considerably. This means the compounded GLP-1 you start today may not be available the same way in six months. It is a real risk for a long-term protocol like weight management.

Practically, if you can afford brand-name Wegovy or Zepbound (with or without insurance), or if you have insurance that covers it, that is the cleaner pharmacological choice — same molecule, FDA oversight, predictable supply, predictable formulary. If cost rules out the brand-name pathway, compounded GLP-1s offered by clinics that disclose their pharmacy partner (ideally a 503B outsourcing facility) and provide a clear formulary statement are the next-best option. Clinics that obscure their compounding source or refuse to name a 503A vs 503B partner are an immediate yellow flag.

What the Trial Numbers Actually Mean

Wegovy's pivotal trial (STEP 1) showed a mean weight loss of 14.9% over 68 weeks at the 2.4 mg dose, versus 2.4% on placebo. Zepbound's pivotal trial (SURMOUNT-1) showed 20.9% over 72 weeks at the 15 mg dose, versus 3.1% on placebo. Both figures are remarkable — historically, lifestyle-only weight-loss programs produce 3-6% loss at 12 months, and pre-GLP-1 weight-loss medications produced 5-10%.

Two cautions about reading these numbers: first, both trials excluded participants with diabetes (a separate trial population) and titrated up to the maintenance dose over 16-20 weeks, which means your first three months on therapy will not look like the trial average. Second, the trials measured percent of body weight at week 68 or 72 against baseline — they did not measure five-year sustained loss. Real-world data is still emerging, but rebound after discontinuation is common, which is why most clinicians and our editorial position favor framing GLP-1 therapy as long-term metabolic medicine rather than a short-term weight-loss tool.

What Good Clinical Oversight Looks Like

GLP-1s are not benign drugs. The FDA labels carry warnings for pancreatitis, gallbladder disease, and (in animal models) thyroid C-cell tumors. The most common side effects — nausea, diarrhea, vomiting, constipation — are dose-dependent and usually titration-related, but they are not trivial: a patient titrating too quickly can lose meaningful weight from sheer GI distress, which is not the goal.

A telehealth clinic that does GLP-1 well will: (a) require a structured intake covering personal and family history of pancreatitis, thyroid cancer, and gallbladder disease; (b) titrate the dose on a defined schedule rather than letting the patient self-escalate; (c) make it easy to message a clinician when side effects appear, rather than gating support behind another consult fee; and (d) ask about adjacent medications — particularly for type 1 or insulin-using type 2 diabetics, where GLP-1s can cause hypoglycemia.

• Clinic does a structured medical history before prescribing, not just BMI screening
• Titration is provider-controlled, not patient-controlled
• Asynchronous messaging is unlimited and free, not gated behind extra consult fees
• The pharmacy partner is named (especially for compounded protocols)
• Refills require a brief check-in, not just a credit-card hit

The Real Monthly Cost

Headline pricing on a telehealth GLP-1 page is rarely the all-in monthly cost. Look for these line items: the program/membership fee, the medication fee at your maintenance dose (not your starting dose), shipping, lab work (some clinics require baseline labs), and any add-on charges for nutrition coaching or premium tiers. Compounded plans on flat-rate pricing avoid the dose-tier surprise; brand-name plans pass through the medication's published wholesale cost plus a markup.

For the 35+ providers in our directory, all-in monthly cost at the maintenance dose ranges from roughly $179/month (low-end compounded with no extras) to $1,400+/month (brand-name Wegovy or Zepbound at retail without insurance). The ranking above factors in this all-in cost, not the marketing-headline number.